Top member reports
No meetings
Consensus community valuation
The consensus valuation is for members only and has been removed from this chart. Click for membership options.
No value forecast available for this company
Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#ASX Announcements
Added 3 years ago

21st September 2021 | AusCann Group Holdings ACN: 008 095 207 | ASX:AC8

AusCann to Accelerate Cannabinoid Drug Development
Program for Human Registration


Key Highlights:

  • AusCann has engaged the CRO division of Cannvalate Pty Ltd to conduct a technical review on the Company’s existing animal data and research assets for the development of cannabinoid-based drug candidates for human registration in the areas of traumatic injury and neurological disorders;
  • The indications being explored by the Company have an initial addressable market of over US$2B globally with a high likelihood of response to cannabinoid therapy;
  • The CRO division of Cannvalate is a cannabinoid-focussed Contract Research Organisation with in-house clinical advisors and sub-consultants specialising in FDA and 505(b)2 registration pathways.
Read More
#ASX Announcements
Added 3 years ago

There was a moment in the past when AC8 back in 2017/18 was on a tear, reaching I think $1.75.  Giddy days.  One direction since then closing yesterday below $0.10.  

CEOs have come and gone, acquisitions been made, restructures and more restructures, clinical trials, registrations...  but not much gets sold...


Key Company Highlights and Financial Commentary for the Year Ended 30 June 2021  


Key Highlights for FY21:

  • Successfully completed the acquisition and integration of CannPal Animal Therapeutics Pty Ltd (CannPal), by way of Scheme of Arrangement, with new leadership in place for the combined entity;
  • Completed 25 subject Phase 1 pharmacokinetic and safety study of AusCann’s hard-shell capsules, using the proprietary Neuvis® platform, achieving all endpoints;
  • Received positive clinical results for 46 dog Phase 2A pilot study for FDA veterinary drug candidate, CPAT-01, confirming improvements in pain, lameness and quality of life in dogs with osteoarthritis;
  • Commenced product registration activities in South Africa and Australia for DermaCann®, a cannabinoid-derived veterinary medicine for anti-inflammatory and immune support in dogs;
  • Finalised the divestment of the Company’s interest in its Chilean joint venture, DayaCann SpA (DayaCann), receiving the first payment instalment associated with the sale;
  • Entered into an agreement to lease the Company’s Wangara facility as part of a revised growth strategy to reduce operating expenses and maximise the value of the Company’s assets;
  • Net assets increased to $44.4m (2020 $34.6m) and net cash used in operations (excluding one-off costs associated with the CannPal acquisition) reduced to $5,759,140 (2020: $10,550,511);
  • Advanced planning for FY22 commercialisation and development of lead pipeline candidates.

30th August 2021AusCann Group Holdings (ASX:AC8) (“AusCann” or “the Company”) is pleased to provide the following commentary to accompany the release of its audited financial results for the year ended 30 June 2021 (FY2021).

Operating Results and Financial Position 

The loss of the consolidated entity for the financial year was $8,641,391 (2020: $7,076,213), which included $212,511 of non-cash share-based payments, a $2,593,417 non-cash impairment of raw material inventories, and once-off costs of $1,172,798 relating to the acquisition of CannPal Animal Therapeutics Limited (CannPal).

Excluding one-off costs associated with the CannPal acquisition, the net cash used in operating activities reduced by 45% in the financial year to $5,759,140 (2020: $10,550,511) due to reductions in statutory expenses, shared resources, operational efficiencies, and a streamlined organisational structure as a result of the CannPal acquisition and a restructuring of the AusCann business.

Direct research and development expenses of $2,947,926 (2020: $2,707,134) accounted for 51% of the Company’s net cash operating cash outflows for FY21 and relates to core value generating activities for the Company’s lead medicinal cannabis programs.

Total income for the Company was up 7% predominately due to the refund from the Australian Taxation Office of $1,561,518 (2020: $1,207,175) in accordance with the Australian Government’s Research and Development Tax Incentive Program.

AusCann remains well funded with net assets of $44,427,696 (2020 $34,635,972) and a net cash position of $13,679,923. The Company is heading into the new year with an improved cost-base, a restructured organisation, and a heavy focus on the development of differentiated, high value cannabinoid-based pharmaceuticals for registration in human and animal pathways. 

A review of operations for the year is set out on page 10 of the Annual Financial Statements. 

To read the full Annual Financial Statements please click here.

Read More
Valuation of $0.700
Added 5 years ago
Like the shift to pharmaceuticals. Clinical trials will be interesting.
Read More